摘要
目的探讨CD19、CD56、CD2在急性髓性白血病(AML)的表达情况及在微小残留病检测中的意义。方法选择AML初发患者130例,采用三组四色荧光标记单克隆抗体组合(CD34/CD13/CD45/CD19、CD34/CD56/CD33/CD45和CD34/CD2/CD33/CD45),用多参数流式细胞术对初发AML病人骨髓细胞进行检测。结果在AML中CD19阳性表达率为2.31%(3/130例),CD56为3.75%(3/80例),而CD2为1.25%(1/80例);在急性早幼粒细胞白血病(M3)无表达。结论CD19、CD56、CD2在急性髓性白血病的表达率很低;CD56、CD2可作为AML微小残留病(MRD)检测的指标;CD19在AML微小残留病检测中无意义。
Objective To study the expression of CD19, CD56 and CD2 in acute myeloid leukemia and their significance in detecting minimal residual disease（MRD）. Methods One hundred and thirty bone marrow specimens of new AML patients were selected, and immunophenotypes were assayed using three sets of 4-color antibodies combination （ CD34/CD13/CD45/CD19, CD34/CD56 / CD33/CD45 and CD34/CD2/CD33/CD45）by multiparameter flow cytometry（MFC）. Results Expression frenquence of CD19 was 2.31%, CD56 was 3.75 %, and CD2 was 1.25 % in AML. None of them were detected in M3. Conclusion Expression frenquence of CD19, CD56, CD2 in AML is low. CD56, CD2 may be markers in detecting MRD in AML, but CD19 could be not.
出处
《山西医科大学学报》
CAS
2007年第9期803-804,827,共3页
Journal of Shanxi Medical University
作者简介
张红灵，女，1969—01生，博士，主治医师．
